May 2013- Volume 9, Issue 5

May 2013

In this Issue

Commentary

Facing the patent cliff head-on

Facing the patent cliff head-on

With the loss of patent protection on so many blockbuster drugs, Big Pharma’s financial outlook is entering a new phase of opportunity.

Out of Order: Attention to detail

Out of Order: Attention to detail

Molecular biological advances have changed our world for the good, and I am the first to jump up and applaud them. But it is equally important that we don’t let the volume of that applause drown out the voices that offer alternative solutions.

Feature

ISSCR 2013 Show Preview (continued)

ISSCR 2013 Show Preview (continued)

Additional stories relevant to ISSCR 11th Annual Meeting in Boston, plus more photos

ISSCR 2013 Show Preview: From stem to stern

ISSCR 2013 Show Preview: From stem to stern

ISSCR meeting keeps up with fast pace of stem cell research by offering increased technology element, expanded poster coverage and more

Diagnostics

To cancer and beyond

To cancer and beyond

CollabRx Partners with Sengenics for molecular diagnostics, with cancer as initial focus area

All about antibodies

All about antibodies

OriGene acquires SDIX’s life-science business assets

A firm foundation for Agios

A firm foundation for Agios

Agios Pharmaceuticals partners with Foundation Medicine for IDH1 and IDH2 cancer metabolism programs

The power of prediction

The power of prediction

CvergenX partners with NCI to predict best candidates for radiation therapy

Omics & Systems Biology

Soaking up some UVP rays

Soaking up some UVP rays

Analytik Jena acquires imaging systems developer UVP and subsidiary

From lab to clinic in the Sunshine State

From lab to clinic in the Sunshine State

First five projects named to pilot Florida Translational Research Program

A sweet deal

A sweet deal

Agilent Technologies and Chungnam National University collaborate on glycomics research education center

Partners in search of a prognosis

Partners in search of a prognosis

OGT granted prostate cancer biomarker license by the ICR

Government Watch

Patent Docs: Supreme Court’s consideration of IP rights exhaustion impacts pharma, biotech industries

Patent Docs: Supreme Court’s consideration of IP rights exhaustion impacts pharma, biotech industries

The U.S. Supreme Court has been considering exhaustion of intellectual property rights this term, and in one case decided and one pending, these considerations could impact the availability of meaningful patent protection for drugs, vaccines and other biological products

Half a loaf, maybe

Half a loaf, maybe

Supreme Court hears arguments challenging patents on breast, ovarian cancer genes

States beg to differ on biosimilar concerns

States beg to differ on biosimilar concerns

Maryland becomes fourth U.S. state to reject laws restricting biosimilar substitution

‘2013: A bad year to have a good idea’

‘2013: A bad year to have a good idea’

Sequestration takes $1.6 billion bite out of NIH-funded research

Tools & Technology

Next-gen data dynamic duo

Next-gen data dynamic duo

IBM and CLC bio pair up to deliver combined turnkey genomics sequencing analytics solution

TAPs for Thermo Fisher

TAPs for Thermo Fisher

Company and U.K.’s U of Birmingham become Technology Alliance Partners to advance LC-MS techniques in life-science research

Gaining ground with genomics

Gaining ground with genomics

NextBio, Genophen partner to advance genomics in personalized medicine

Core Informatics and OpenEye Scientific Software forge partnership

Core Informatics and OpenEye Scientific Software forge partnership

Core Informatics and OpenEye Scientific Software announce partnership and their integration of OpenEye cheminformatics software into Core Informatics’ web-based Laboratory Information Management System and Electronic Lab Notebook

Rockland Immunochemicals acquires antibody line from 21st Century Biochemicals

Rockland Immunochemicals acquires antibody line from 21st Century Biochemicals

Biotechnology company Rockland Immunochemicals Inc. has acquired the Epi-Plus antibody product line from 21st Century Biochemicals Inc.

Life for Thermo

Life for Thermo

Thermo Fisher Scientific acquires Life Technologies for $13.6 billion

Global News

Developing answers for developing nations

Developing answers for developing nations

Five Japanese pharmas form public-private partnership with their government to help developing countries fight infectious diseases

A partnership with some pep(tides)

A partnership with some pep(tides)

Ipsen, PeptiDream team up for therapeutic peptides to treat serious conditions

Getting personal about profiling

Getting personal about profiling

PerkinElmer will team up with China’s National Center for Drug Screening to advance personalized medicine and drug profiling

Coordinated TAKTIC

Coordinated TAKTIC

Six-way partnership attempts synergy in inhibiting protein kinases to develop novel drugs

Two ways to look at it

Two ways to look at it

Roche looks to combine Isis’ antisense oligonucleotide program with its own ‘brain shuttle’ program to take down Huntington’s disease

Research & Development

Nanomedicine: The next (not-so-) big thing

Nanomedicine: The next (not-so-) big thing

BIND Therapeutics announces collaboration with Pfizer to develop nanoparticle-based therapeutics

MedImmune makes a move

MedImmune makes a move

MedImmune acquires AlphaCore, gains novel compound based on LCAT enzyme

Straight A's with ADCs

Straight A's with ADCs

Astellas, Ambrx to collaborate on ADCs for oncology targets

A pair of model-building aficionados

A pair of model-building aficionados

Crown Bioscience and Horizon Discovery forge two-year deal to offer combined solutions for in-vivo oncology model development

New hope for a cruel disease

New hope for a cruel disease

Israel’s BrainStorm partners with New York’s Dana-Farber in Phase II ALS clinical trial to treat Lou Gehrig’s disease

Editor's Focus

The many colors of sequestration

The many colors of sequestration

In researching our cover story on the sequestration -- or, put in very stark, black-and-white terms, $85 billion in across-the-board cuts to federal government spending -- and how it is expected to affect biomedical research in every state, I was treated to a slew of colorful comparisons by researchers, trade groups and government leaders, as they grapple to explain the hit they will take when the NIH is forced to cut its budget by 5.1 percent, or $1.6 billion, this fiscal year.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue